SCHEMBL5888071

SCHEMBL5888071

CC1(CN(C(=O)c2cccc(Cl)c2Cl)[C@H]2CCN(C(=O)O)C2)CC1

nearest known ligand 0.45

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 10/20 0.45
SLC6A4 P31645 10/20 0.45
SLC6A3 Q01959 10/20 0.45
KCNH2 Q12809 6/20 0.43
OPRK1 P41145 1/20 0.43
CCR5 P51681 1/20 0.40
P2RX7 Q99572 3/20 0.36
SLC6A9 P48067 1/20 0.36
RAB9A P51151 1/20 0.36
BDKRB1 P46663 2/20 0.35
UBE2M P61081 1/20 0.35
DCUN1D1 Q96GG9 1/20 0.35
CYP2C9 P11712 1/20 0.35
CYP2C19 P33261 1/20 0.35
HTR2B P41595 1/20 0.35
MAPK14 Q16539 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5888056 0.91 KCNH2 (0.44) SLC6A2SLC6A4SLC6A3KCNH2CCR5
SCHEMBL5201833 0.87 USP30 (0.45) SLC6A2SLC6A4SLC6A3KCNH2OPRK1
SCHEMBL4635761 0.83 SLC6A2 (0.62) SLC6A2SLC6A4SLC6A3KCNH2OPRK1
SCHEMBL5887638 0.81 SLC6A2 (0.51) SLC6A2SLC6A4SLC6A3KCNH2OPRK1
SCHEMBL4121587 0.80 SLC6A2 (0.44) SLC6A2SLC6A4SLC6A3KCNH2CCR5
SCHEMBL4512920 0.80 SLC6A2 (0.53) SLC6A2SLC6A4SLC6A3KCNH2OPRK1
SCHEMBL4112308 0.78 SLC6A2 (0.43) SLC6A2SLC6A4SLC6A3KCNH2
SCHEMBL5888110 0.78 SLC6A4 (0.74) SLC6A2SLC6A4SLC6A3KCNH2OPRK1
SCHEMBL5888157 0.77 SLC6A2 (0.58) SLC6A2SLC6A4SLC6A3KCNH2OPRK1
Hydrochloric Acid SCHEMBL5888099 0.77 SLC6A4 (0.72) SLC6A2SLC6A4SLC6A3KCNH2OPRK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7122683-B2 Amides useful as monoamine re-uptake inhibitors PFIZER INC. (US) 2006-10-17 US disclosed
US-20060111429-A1 Substituted N-[pyrrolidin-3-yl] benzamides or naphthamides; serotonin and noradrenaline receptor antagonists; urinary incontinence; arylation of the amino pyrrolidine with a carboxylic acid or acyl halide and then deprotecting PFIZER INC 2006-05-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060111429-A1 Substituted N-[pyrrolidin-3-yl] benzamides or naphthamides; serotonin and noradrenaline receptor antagonists; urinary incontinence; arylation of the amino pyrrolidine with a carboxylic acid or acyl halide and then deprotecting ADRB3, AOC3, HRH4 SLC6A2 33/4885SLC6A4 49/4885SLC6A3 41/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.